Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients

Completed

• Conditions: Non Small Cell Lung Cancer; Circulating Tumor Cell

• Registration Number: NCT05619562
• Lead Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic

Brief Summary

To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Primary Completion: 2013-04
• Study Completion: 2015-12
• Status Verified: 2022-11
• Study First Submitted: 2022-11-09
• Study First Submitted QC: 2022-11-09
• Last Update Submitted: 2022-11-09
• Study First Posted: 2022-11-17
• Last Update Posted: 2022-11-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 166

Inclusion Criteria

Non-small cell lung cancer, non-metastatic

Exclusion Criteria

Prior neoadjuvant chemoradiotherapy Prior lung cancer Cancer duplicity

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells in lung cancer patients	30 days	The absolute gene expression of CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells(CTCs) isolated from peripheral blood, tumour draining blood and bone marrow samples of lung cancer patients will be measured using real-time RT-PCR method. The gene expression will be normalized per microgram of total mRNA.

Secondary Outcome Measures

Name	Time	Method
Cancer specific survival in CTC positive NSCLC patients	5 years	The cancer specific survival, overall survival and disease free survival will be measured from the time of diagnosis to the time of event. Two groups of patients will be compared: A: Patients with the presence of CTCs in peripheral blood, tumour draining blood and bone marrow before NSCLC surgery as described in primary outcome measure.; B: Patients with the absence e of CTCs in peripheral blood, tumour draining blood and bone marrow before NSCLC surgery as described in primary outcome measure.

Trial Locations

Locations (1)

University Hospital Olomouc; 🇨🇿 Olomouc, Česká Republika, Czechia